<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406675</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01213-36</org_study_id>
    <nct_id>NCT04406675</nct_id>
  </id_info>
  <brief_title>Social Cognition in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>COSISLA</acronym>
  <official_title>Social Cognition in Patients With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis, also known as Charcot disease, is a neurodegenerative disease&#xD;
      evidenced by gradual paralysis of the muscles involved in voluntary motor function. The&#xD;
      clinical hallmark of Amyotrophic Lateral Sclerosis is the combination of upper and lower&#xD;
      motor neuron signs and symptoms. The most recent studies suggest that up to 50% of&#xD;
      Amyotrophic Lateral Sclerosis patients demonstrate mild to moderate cognitive disturbance.&#xD;
      Impaired social cognition, including a deficit in the recognition of facial emotions and the&#xD;
      identification of vocal prosody, is recognized as a part of the cognitive phenotype of&#xD;
      Amyotrophic Lateral Sclerosis, with crucial implications for patients' and caregivers'&#xD;
      training. However, studies remain scarce and the data acquired must be supported. The&#xD;
      evolution of these manifestations during the disease is still poorly understood.&#xD;
&#xD;
      In this study the investigators aim to assess the social cognition capacities of patients&#xD;
      with Amyotrophic Lateral Sclerosis compared to healthy matched control subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the social cognition capacities</measure>
    <time_frame>One day</time_frame>
    <description>Evaluate the social cognition capacities of patients with Amyotrophic Lateral Sclerosis compared to control subjects using dynamic social cognition tests : Movie for the Assessment of Social Cognition. The maximum score is 48 points. The higher the score for correct answers, the better the performance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Social Cognition</condition>
  <arm_group>
    <arm_group_label>Patients Amyotrophic Lateral Sclerosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychological test</intervention_name>
    <description>neuropsychological test</description>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_label>Patients Amyotrophic Lateral Sclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient Amyotrophic Lateral Sclerosis :&#xD;
&#xD;
          -  Education of at least 7 years&#xD;
&#xD;
          -  Native language: French&#xD;
&#xD;
          -  Patients Amyotrophic Lateral Sclerosis&#xD;
&#xD;
          -  Signature of informed consent to participate in the study&#xD;
&#xD;
          -  Accompanied patient&#xD;
&#xD;
        Control subject :&#xD;
&#xD;
          -  People without any pathology&#xD;
&#xD;
          -  Education of at least 7 years&#xD;
&#xD;
          -  Native language: French&#xD;
&#xD;
          -  Signature of informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient Amyotrophic Lateral Sclerosis and control subject :&#xD;
&#xD;
          -  Simultaneous participation in another interventional protocol with experimental&#xD;
             treatment&#xD;
&#xD;
          -  Inability to perform cognitive study tests&#xD;
&#xD;
          -  Pregnant, lactating or parturient women&#xD;
&#xD;
          -  Persons deprived of their liberty by administrative or judicial decision&#xD;
&#xD;
          -  Persons under psychiatric care under duress&#xD;
&#xD;
          -  Persons subject to legal protection measures&#xD;
&#xD;
          -  Persons out of state to express their consent&#xD;
&#xD;
          -  People not affiliated or not beneficiaries of a social security scheme&#xD;
&#xD;
          -  History likely to disturb cognition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cassereau Julien</last_name>
    <phone>0241355615</phone>
    <email>jucassereau@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muller Jeanne</last_name>
    <email>jeanne.muller@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muller Jeanne</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

